Daniel J. Chai, M.D. is the Founder and Managing Partner of Turret Capital Management, a healthcare venture building and investment firm based in New York. Dr. Chai has over 20 years of experience as an investor and healthcare entrepreneur. Prior to forming Turret Capital in 2016, Daniel was a Portfolio Manager at several leading hedge funds and investment firms including Citadel, UBS and Neuberger Berman. Dr. Chai was an early investor and board member of Nexgen Spine (acquired by Stryker Corporation), a co-founder of Serenikey Therapeutics (now Terran BioSciences), and a board member of TeraImmune Inc. (acquired by Baudax Bio). Daniel graduated as an Angell Scholar from the University of Michigan and received his B.S. degree with Honors. He received his M.D. degree from Columbia University’s College of Physician & Surgeons.

Henry has over 15 years of financial services experience and global VC/PE with transaction experience across Asia and the US. Most recently, he was Vice President of US Operations at Magna Investments, one of South Korea’s leading healthcare VC firms. Henry works closely with American and Korean life sciences firms to in-license/out-license assets and complete crossborder transactions and has a transaction focus in medical and diagnostics devices. Henry holds a B.S. from the University of Michigan with majors in Biopsychology and Cognitive Science.

Gail has over 30 years of experience in the healthcare industry. She was previously the CEO & President of Vermillion Inc., a leading diagnostics company focused on the development and commercialization of novel multi-proteomics tests. There, Gail forged a partnership with Quest Diagnostics and oversaw the commercial launch of the first FDA-cleared blood test to help diagnose ovarian cancer. Prior to her role at Vermillion, she served on the Executive Management team at Laboratory Corporation of America (NASDAQ: LH), one of the world’s leading diagnostic companies. Her current board appointments include Sword Diagnostics, Inc., NxPrenatal, Inc., and Chembio (NASDAQ: CEMI). In August of 2018, she was appointed as the Chief Business Advisor for the Dell Medical School Catalyst/UT Board. Gail earned a B.S. from the University of Florida and completed an executive management program at the Northwestern University Kellogg School of Management.

Lauren has over 20 years of operating and investment experience in the healthcare industry. She is the founder and CEO of Minleigh LLC, a healthcare focused strategic advisory firm. Prior to this Lauren was a Co-Founder of Tokum Capital Management, a global healthcare hedge fund, which later merged with Perella Weinberg Partners. She received her Ph.D from Columbia University's College of Physicians & Surgeons, her M.B.A. from Columbia Business School, and B.A. with Honors from Wellesley College.

Melissa is an Operating Partner at Turret Capital. She brings deep operational experience informed from 20 years in healthcare strategy and operations across drugs, devices, and digital health. In Silicon Valley where she resides, Melissa led marketing and market development at two digital health startups that had successful exits (Propeller Health acquired by ResMed, and Physera acquired by Omada Health). At global BioPharma companies (Roche/Genentech, Gilead Sciences), Melissa led commercial planning and advised R&D and business development teams on the competitive landscape in a variety of disease areas. Early in her career, she was a sell side equity research analyst at UBS and JP Morgan covering US small & mid cap healthcare technology companies. Melissa has a PhD in Biology from Columbia University, and a BA in Biology with a double major in International Studies from Washington University in St Louis. In addition to her current role at Turret Capital, Melissa is the CEO & Founder of Piggyback Health, a consulting firm that advises investors and industry on early stage Femtech and next generation women’s health.

Lawrence has approximately ten years of experience in the global pharmaceuticals industry. He was most recently Associate Director at Bayer Pharmaceuticals. At Bayer, he was in charge of Global Regulatory Strategy for innovative products where he successfully coordinated and achieved regulatory milestones involving the FDA and CFD. Lawrence holds an A.B. from Peking University, an M.D. from Peking Union Medical College, and an M.P.H. from Harvard University.

Anthony Gallo has more than 30 years of experience in the financial services industry. He has an extensive background with financial and operational administration of alternative asset fund structures, fund of funds, managed accounts, and family office accounting and tax. Prior to founding Concept Fund Services, Anthony was the CFO and Managing Member of ConceptOne, LLC which provided risk and performance analytic solutions, middle and back office support, fund administration, outsourced CFO, and regulatory reporting services to investment managers. Before his career in hedge funds, he was the CFO for Abacus and Associates, a Family Office, and started his public accounting career with Richard A. Eisner and Co. Anthony earned a B.A. in Business Administration from Hofstra University.

Frank Borchetta, J.D. – Frank has over 15 years experience in Intellectual Property law. He began his legal career by assisting pharmaceutical and biotech companies in various patent matters, including patent prosecution and litigation. Frank has worked at several high profile law firms including Loeb & Loeb. He was also an attorney at Ascent Biomedical Ventures, where he was responsible for patent portfolio analysis. Frank also has direct experience operating early stage companies as the Chief Executive Officer of Repairogen Corporation, a skincare company developing products based on DNA-repair technology. Frank received his J.D. from Boston University.

Ms. Jambhekar brings over 20 years of experience in the areas of product development, product safety, quality assurance and compliance, clinical operations, supply chain management and both U.S. and international regulatory affairs. Over the course of her career she has managed over 250 NDA/IND/ANDA/PMA/510(k)s. Currently, Ms. Jambhekar serves as the President of PBS Regulatory Consulting Group. Ms. Jambhekar held various roles of increasing responsibility at Paramount BioSciences, Ethicon, a J&J company, Baxter AAC and Bristol-Myers Squibb. Ms. Jambhekar holds her M.Sc. in Organic & Biochemistry and her M.S. in Pharmacy.

Mark has over ten years of investment experience in the Greater China markets. He was most recently a Vice President at Huarong International Financial Holding Limited, a Hong Kong listed licensed company (0993.HK), and a subsidiary of China Huarong Asset Management Co., Ltd. (2799.HK), one of four asset management companies established by the Ministry of Finance of PRC. Prior to that, Mark served as Business Development Manager at Hao Tian Development Limited, a Hong Kong listed company (0474.HK), where he focused on growing opportunities in Greater China. Mark holds a BCom in Finance from the Haskyne School of Business at University of Calgary and an M.S. in International Banking and Finance from Ling Nan University